Literature DB >> 27557547

A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis.

Raisuke Iijima1, Gjin Ndrepepa2, Vivien Kujath3, Yukinori Harada3, Sebastian Kufner3, Heribert Schunkert3,4, Masato Nakamura1, Adnan Kastrati3,4.   

Abstract

The frequency and pattern of progression or regression of coronary atherosclerosis in contemporary patients with diabetes remain unknown. This study included 605 patients with coronary artery disease (CAD). Two coronary angiographic examinations at baseline and after 2 years were performed. The analysis focused on non-stented segments with diameter stenosis ≥25 %. Atherosclerosis progression (or regression) was defined as a decrease (or increase) in the mean minimal lumen diameter (MLD) in the 2-year angiogram compared to mean MLD in the baseline angiogram of >0.2 mm. Statins were prescribed in 576 patients (95.2 %). The primary outcome was atherosclerosis progression or regression in the 2-year angiogram. One hundred sixty-nine patients (28 %) had diabetes. Diabetic patients had greater reduction of mean MLD in the 24 angiogram compared to baseline angiogram than nondiabetic patients (0.11 ± 0.18 vs. -0.08 ± 0.15 mm, P < 0.001). Atherosclerosis progression was observed in 37 patients with diabetes and 16 nondiabetic patients (21.9 vs. 3.7 %; P < 0.001). Atherosclerosis regression was observed in two diabetic patients and 78 nondiabetic patients (1.2 vs. 17.9 %; P < 0.001). A progression pattern across all coronary segments was observed in 70 patients (41.4 %) with diabetes and 60 patients (13.8 %) without diabetes (P < 0.001). Diabetic patients with a low-density lipoprotein cholesterol ≥70 mg/dl showed more atherosclerosis progression than diabetic patients with LDL cholesterol <70 mg/dl (delta-MLD: 0.12 ± 0.19 vs. 0.08 ± 0.16 mm; P = 0.04). In conclusion, in contemporary patients with CAD treated with moderate-intensity statin therapy, diabetes is associated with the increased risk of progression and decreased probability of regression of coronary atherosclerosis.

Entities:  

Keywords:  Atherosclerosis; Coronary artery disease; Diabetes; Progression; Regression; Statins

Mesh:

Substances:

Year:  2016        PMID: 27557547     DOI: 10.1007/s00380-016-0889-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  24 in total

Review 1.  Quantitative coronary angiography in regression trials: a review of methodologic considerations, endpoint selection, and limitations.

Authors:  Alexandra J Lansky; Kartik Desai; Martin B Leon
Journal:  Am J Cardiol       Date:  2002-02-21       Impact factor: 2.778

2.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.

Authors:  W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

3.  Impact of type 2 diabetes on serial changes in tissue characteristics of coronary plaques: an integrated backscatter intravascular ultrasound analysis.

Authors:  Shinji Inaba; Hideki Okayama; Jun-ichi Funada; Haruhiko Higashi; Makoto Saito; Toyofumi Yoshii; Go Hiasa; Takumi Sumimoto; Yasunori Takata; Kazuhisa Nishimura; Katsuji Inoue; Akiyoshi Ogimoto; Jitsuo Higaki
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-02-24       Impact factor: 6.875

4.  IVUS Virtual Histology: Unvalidated Gimmick or Useful Technique?

Authors:  Steven E Nissen
Journal:  J Am Coll Cardiol       Date:  2016-04-19       Impact factor: 24.094

5.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.

Authors:  B Pitt; G B Mancini; S G Ellis; H S Rosman; J S Park; M E McGovern
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

6.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

7.  Application of intravascular ultrasound for detection and quantitation of coronary atherosclerosis.

Authors:  S E Nissen; J C Gurley
Journal:  Int J Card Imaging       Date:  1991

8.  Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).

Authors:  Rishi Puri; Steven E Nissen; Ransi Somaratne; Leslie Cho; John J P Kastelein; Christie M Ballantyne; Wolfgang Koenig; Todd J Anderson; Jingyuan Yang; Helina Kassahun; Scott M Wasserman; Robert Scott; Marilyn Borgman; Stephen J Nicholls
Journal:  Am Heart J       Date:  2016-02-17       Impact factor: 4.749

9.  Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.

Authors:  Gjin Ndrepepa; Raisuke Iijima; Sebastian Kufner; Siegmund Braun; Salvatore Cassese; Robert A Byrne; Jonas Sorges; Stefanie Schulz-Schüpke; Petra Hoppmann; Massimiliano Fussaro; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati
Journal:  Am Heart J       Date:  2016-05-06       Impact factor: 4.749

10.  High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.

Authors:  Brian Stegman; Rishi Puri; Leslie Cho; Mingyuan Shao; Christie M Ballantyne; Phillip J Barter; M John Chapman; Raimund Erbel; Peter Libby; Joel S Raichlen; Kiyoko Uno; Yu Kataoka; Steven E Nissen; Stephen J Nicholls
Journal:  Diabetes Care       Date:  2014-09-04       Impact factor: 19.112

View more
  4 in total

1.  Pravastatin improves postprandial endothelial dysfunction and hemorheological deterioration in patients with effort angina pectoris.

Authors:  Tomio Umemoto; Takanori Yasu; Kenshiro Arao; Nahoko Ikeda; Yasuto Horie; Hiroyuki Sugimura; Masanobu Kawakami; Hideo Fujita; Shin-Ichi Momomura
Journal:  Heart Vessels       Date:  2017-04-10       Impact factor: 2.037

2.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

3.  Association between coronary artery atherosclerosis and plasma glucose levels assessed by dual-source computed tomography.

Authors:  Yi Yu; Zhiwen Zhou; Kun Sun; Lili Xi; Lina Zhang; Lingwei Yu; Jing Wang; Jiayi Zheng; Ming Ding
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

4.  Perioperative Cardiometabolic Targets and Coronary Artery Bypass Surgery Mortality in Patients With Diabetes.

Authors:  John P Skendelas; Donna K Phan; Patricia Friedmann; Carlos J Rodriguez; Daniel Stein; Armin Arbab-Zadeh; Stephen J Forest; Leandro Slipczuk
Journal:  J Am Heart Assoc       Date:  2022-04-27       Impact factor: 6.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.